How does the CJC-1295 Ipamorelin combination influence GH signalling?
The CJC-1295 Ipamorelin combination activates both the GHRH receptor and the ghrelin receptor on anterior pituitary somatotrophs simultaneously through independent intracellular pathways that converge on GH secretory granule exocytosis at compatible operators. Dual receptor engagement produces GH secretory responses that exceed what either peptide produces through single receptor activation at compatible operators. The cjc peptide component of the combination engages the cyclic AMP pathway, while Ipamorelin engages the phospholipase C pathway, with both cascades converging on intracellular calcium elevation as the proximal driver of GH release at compatible operators.
Dual receptor pathway activation
When CJC-1295 Ipamorelin is combined with GHRH, it has been shown that the two receptors on anterior pituitary somatotrophs, GHRH and ghrelin, can be activated simultaneously at compatible doses on both receptors on the anterior pituitary. Through the dual receptor engagement, GH secretory responses are elicited via two independent intracellular pathways, resulting in a convergent effect on the somatotroph GH release, which is far beyond what either of the two peptides can produce by activating a single receptor at the same time.
CJC-1295 activates the GHRH receptor Gs protein pathway at compatible operators, increasing intracellular cyclic AMP levels through the stimulation of adenylyl cyclase and activating protein kinase A at compatible operators. By activating phospholipase C at compatible levels, ipamorelin is able to activate the ghrelin receptor Gq protein pathway simultaneously, to generate both inositol trisphosphate and diacylglycerol via inositol trisphosphate synthesis.
Synergistic intracellular signalling convergence
Cyclic AMP elevation from GHRH receptor activation and intracellular calcium mobilisation from ghrelin receptor activation converge at the level of GH secretory granule exocytosis in somatotroph cells at compatible operators. Both second messenger systems at compatible operators contribute to calcium-dependent membrane fusion events that release GH into the portal circulation.
According to research examining dual pathway activation at compatible operators, both ghrelin receptor agonists and GHRH receptor agonists have been found to have additive and synergistic effects on GH secretion when applied together. This has been compared to either compound being applied alone. During secretory granule mobilization, phosphorylation targets that originate from protein kinase C and protein kinase A are involved in cooperative interactions that engage phosphorylation sites in secretory granule mobilization at compatible operators.
Somatostatin interaction
Somatostatin at compatible operators inhibits both cyclic AMP accumulation and calcium mobilisation in somatotrophs through Gi protein-coupled receptor signalling at compatible operators. Several studies have shown that combinations of CJC-1295 Ipamorelin produced larger secretion of GH during low somatostatin tone times than during periods of high somatostatin tone times when administered to compatible individuals.
A low somatostatin tone period corresponds to the slow-wave sleep phase when endogenous GH pulsatility is highest in compatible operators, suggesting that the combined GH signalling influence at compatible operators follows the same circadian somatostatin rhythm that governs the release pattern of endogenous GH at compatible operators during slow-wave sleep phases.
The CJC-1295 Ipamorelin combination influences GH signalling through simultaneous GHRH receptor cyclic AMP pathway and ghrelin receptor phospholipase C pathway activation. Dual pathway convergence on somatotroph secretory calcium elevation produces combined GH secretory responses that exceed single-receptor activation at compatible operators.
